Camarena-Reynoso HR, Ariza-Villaro P, Mata MP, Leos-Acosta CA, Shuck-Bello CE, Cantellano-Orozco M, Vázquez-Ortega LS, Andrade-Platas JD, Fernández-Carreno A, Morales-Montor JG, Pacheco-Gahbler C, Calderón-Ferro F

Language: Spanish
References: 25
Page: 262-267
PDF size: 131.64 Kb.

ABSTRACT

Background: Testicular cancer represents between 1% and 1.5% of neoplasms in men and 5% of the urological tumors. It is the most frequent cancer in men between the ages of 15 and 45 years. Ninety-five percent of testicular tumors are composed of malignant germ cells and only 5% are bilateral. Currently, there is a 95% cure rate for low stage testicular cancer. The percentage is lower for more advanced tumors. Early and interdisciplinary treatment including chemotherapy, radiotherapy and surgery are factors attributing to the high cure rate.
Objective: To determine the testicular cancer survival rate.
Materials and methods: A survival analysis crosssectional study was carried out. Case records of all patients diagnosed with testicular cancer from January 1989 to October 2007 were reviewed. Multiple variables were analyzed. Descriptive statistics, survival analysis and proportional Kaplan-Meier and Cox curves were employed. Statistical significance was considered when P ≤ 0.05.
Results: From a total of 307 patients, 184 met the study inclusion criteria. Mean age was 29 years. There were 25 deaths over an 18-year period and the general survival rate was 86%. Ninety-six percent of patients presented with germ cell tumors, 44% with seminomatous tumors and 56% with non-seminomatous tumors. In relation to disease stage, percentage results were as follows: 1a (33.5%), 1b (11%), 1c (15.5%), 2a (6%), 2b (7%), 2c (9%), 3a (3%), 3b (6.5%) and 3c (8.5%). A total of 81.5% of patients were in the good prognosis category, 12.5% in the intermediate category and 6% in the poor prognosis category. The survival rate was lower in the intermediate and poor prognosis groups with p ‹ 0.01. A total of 40.5% of patients were left in observation, 47.5% were given chemotherapy, 7.5% were given radiotherapy and 4.5% underwent chemotherapy and radiotherapy.
Conclusions: In contrast to the national and international literature, testicular cancer is the second most common cancer seen in medical consultation in our hospital. The majority of patients have a favorable progression that is principally dependent on the histology, stage and risk factors of their disease.

REFERENCES

1. Brown LM, Pottern LM, Hoover RN et al. Testicular cancer in the United States: trends in incidence and mortality. Int J Epidemiol 1986; 15:164-170.

2. Richie JP. Neoplasms of the testis. In: Walsh PC et al. Campbell’s urology. 9th ed. Philadelphia: WB Saunder Elsevier 2007:893- 935.

3. Huyghe E, Mastuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5-11.

4. McGlynn KA, Devesa SS et al. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97:63-70.

5. Bosl GJ, Motzer RJ. Testicular germ cell cancer. N Engl J Med 1997;337:242-253.

6. Jones A, Fergus JN, Capman J, Houghton L. Is surveillance for stage I germ cell tumours of the testis appropriate outsite a specialist centre? BJU Int 1999;84:79-84.

7. Albers P, Albrecht F et al. Guidelines on testicular cancer. In: European Association of Urology Guidelines. Drukkerij Gelderland BV, Arnhem-the Netherlands, 2007.

8. Mostofi FK, Sobin LH. Histological typing of testis tumors. Geneva Switzerland: World Health Organization, 1977.

9. Osterlind A, Berthelsen JG et al. Risk of bilateral testicular germ cell tumors in Denmark: 1960-1984. J Natl Cancer Inst 1991;83:1391-1395.

10. Giwercman A, Bruun E et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidisim. J Urol 1989;142:998-1002.

11. Moller H, Prener A et al. Testicular Cancer, cryptorchidism, inguinal hernia, testicular atrophy a genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7:264-274.

12. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer. Cancer 1997;80:1954-1960.

13. Viveros Contreras C, Lugo García JA et al. Cáncer de Testículo. Rev del HJ-Mex 1996;65(1) enero-marzo.

14. Hamdy F, Basler J. Testicular Cancer. In: Management of Urologic Malignancies. Churchill Livingstone. Elsevier Science Limited, 2002:415-476.

15. Comiter CU, Benson CJ et al. Nonpalpable intratesticular masses detected sonographically. J Urol 1995;154:1367-1369.

16. Betanzos González C, Castro Ibarra M, Manzanilla García H. Estudio Comparativo entre hallazgos ecográficos y hallazgos histopatológicos de las neoplasias testiculares de células germinales. Anales de Radiología México 2004;4:271-279.

17. Seller MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a Cochrane evidence based systematic review. Cancer Treat Rev 2002;28:237-253.

18. Leiboitch I et al. Improved accuracy of computerized tomography based clinical staging in low stage no seminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759-1763.

19. Sobin LH, Wittekind Ch, editors UICC: TNM classification of malignant tumors. 6th ed. Wiley-Liss, 2002.

20. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.

21. Registro Histopatológico de Neoplasias Malignas de México, 2000.

22. Registro Histopatológico de Neoplasias Malignas de México, 2001.

23. Mohar A et al. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Pública Mex 1997;39:253-258.

24. Viveros Contreras y cols. Cáncer de Testículo. Rev del HJ-Mex 1998;65(1) enero-marzo.

25. Registro Histopatológico de Neoplasias Malignas de México, 2003.